Our results, based on human and mouse cell lines, suggest that the MEKi and mtPKCi combination may be effective in a large spectrum of mut KRAS lung cancers regardless of the type of KRAS mutation or additional concurrent alterations in tumor suppressor genes. This evidence concerns the gene KRAS and lung cancer.